Courtagen Life Sciences, Inc. Appoints Thomas Fairfield To The Company's Board Of Directors.

WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences, Inc., a commercial-stage, innovative molecular information company that sells proprietary genomic diagnostic and drug metabolism assays for pediatric neurology disorders, announced today the appointment of Thomas Fairfield to the company's Board of Directors.

"Tom has a wealth of legal, M&A, and operating experience," states Brian McKernan, Chief Executive Officer of Courtagen. "We look forward to adding Tom's valuable perspectives to our Board of Directors."

Suggested Articles

Forma's lead asset, an IDH1 inhibitor, cleared cancer in one-third of patients with relapsed or refractory acute myeloid leukemia.

A type of white blood cell known as a granulocyte secretes growth factors that help axons of the central nervous system regenerate, researchers found.

The deal, which features an additional $2 billion in milestones, will give Bayer control of an AAV platform and a clinical-phase pipeline.